Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

Inclusion Criteria: * Histologically confirmed diagnosis of resectable gastric adenocarcinoma or adenocarcinoma of the esophagogastric junction (type II and type III according to Siewerts classification) * Macroscopic peritoneal carcinomatosis (stage P1-4 according to Gilly et al., appendix 1) * Patients potentially eligible for gastrectomy after primary systemic (and intraperitoneal) treatment * Signed and dated informed consent before the start of specific protocol procedures * Age \> 18 years * ECOG Performance Status of 0 or 1 * Life expectancy of at least 12 weeks * Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening * Hemoglobin \> 10.0 g/dl * Leukocyte count \> 4.000/μl; absolute neutrophil count (ANC) \> 2.000/μl * Platelet count \> = 100.000/µl * Total bilirubin \< 1,5 times the upper limit of normal * ALT and AST \< 3 x upper limit of normal * Alkaline phosphatase \< 5 x ULN * Serum creatinine \< 1.5 x upper limit of normal and creatinine clearance \> 60 ml/min * The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations Exclusion Criteria: * Distant metastasis other than peritoneal seedings * Prior diagnosis of any malignancy not cured by surgery alone less than 5 years before study entry * Clinically significant cardiovascular diseas…